THE RECEPTOR FOR UROKINASE PLASMINOGEN-ACTIVATOR IS PRESENT IN PLASMA FROM HEALTHY DONORS AND ELEVATED IN PATIENTS WITH PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA

被引:92
作者
RONNE, E [1 ]
PAPPOT, H [1 ]
GRONDAHLHANSEN, J [1 ]
HOYERHANSEN, G [1 ]
PLESNER, T [1 ]
HANSEN, NE [1 ]
DANO, K [1 ]
机构
[1] HERLEV HOSP,DEPT MED & HAEMATOL 1,COPENHAGEN,DENMARK
关键词
UROKINASE; UROKINASE RECEPTOR; PLASMINOGEN ACTIVATION; THROMBOSIS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA;
D O I
10.1111/j.1365-2141.1995.tb08366.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The urokinase plasminogen activator (uPA) is a proteolytic enzyme which converts the proenzyme plasminogen to the active serine protease plasmin. A cell surface receptor for uPA (uPAR) is attached to the cell membrane by a glycosyl-phosphatidylinositol anchor. Binding of uPA to uPAR leads to an enhanced plasmin formation and thereby an amplification of pericellular proteolysis. We have shown previously that uPAR is expressed on normal blood monocytes and granulocytes, but is deficient on affected blood monocytes and granulocytes in patients with paroxysmal nocturnal haemoglobinuria (PNH), and that uPAR is present in plasma from these patients. In this study a newly established sensitive enzyme-linked immunosorbent assay (ELISA) has been applied for quantitation of uPAR in plasma. Unexpectedly, we found that uPAR is not only present in PNH plasma but also in plasma from healthy individuals. In 39 healthy individuals the mean plasma-uPAR value +/- SD was 31 +/- 15 pM, median 28 (range 11-108), and the corresponding value for six PNH patients was 116 +/- 67 pM, median 90 (range 61-228). The elevated uPAR-level in PNH patients was highly significant (Mann-Whitney test; P < 0.0001), and may possibly contribute to the propensity for thrombosis in PNH by inhibition of the fibrinolytic system. Binding of pro-uPA by uPAR in plasma may interfere with the appropriate binding of pro-uPA to cell-bound uPAR and therefore inhibit cell-associated plasmin generation and fibrinolysis. It is likely that the uPAR in normal plasma reflects the overall level of activity of the uPAR-mediated cell surface proteolysis. The present ELISA may be used for studies of uPAR levels in plasma from patients with conditions in which this activity might be increased, such as cancer and inflammatory disorders. Future studies will determine if uPAR in plasma is a parameter of clinical importance in these diseases.
引用
收藏
页码:576 / 581
页数:6
相关论文
共 39 条
[1]   CEREBRAL VENOUS THROMBOSIS IN PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA - REPORT OF 2 CASES [J].
ALHAKIM, M ;
KATIRJI, MB ;
OSORIO, I ;
WEISMAN, R .
NEUROLOGY, 1993, 43 (04) :742-746
[2]  
BEHRENDT N, 1990, J BIOL CHEM, V265, P6453
[3]   ULTRASONIC DEMONSTRATION OF CLINICAL AND SUBCLINICAL HEPATIC VENOUS THROMBOSIS IN PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA [J].
BIRGENS, HS ;
HANCKE, S ;
ROSENKLINT, A ;
HANSEN, NE .
BRITISH JOURNAL OF HAEMATOLOGY, 1986, 64 (04) :737-743
[4]   UROKINASE-TYPE PLASMINOGEN-ACTIVATOR - PROENZYME, RECEPTOR, AND INHIBITORS [J].
BLASI, F ;
VASSALLI, JD ;
DANO, K .
JOURNAL OF CELL BIOLOGY, 1987, 104 (04) :801-804
[5]  
DANO K, 1993, PORTL PR P, P239
[6]   MEMBRANE-PROTEINS WITH SOLUBLE COUNTERPARTS - ROLE OF PROTEOLYSIS IN THE RELEASE OF TRANSMEMBRANE PROTEINS [J].
EHLERS, MRW ;
RIORDAN, JF .
BIOCHEMISTRY, 1991, 30 (42) :10065-10074
[7]  
ELLIS V, 1991, J BIOL CHEM, V266, P12752
[8]   THE UROKINASE RECEPTOR - INVOLVEMENT IN CELL-SURFACE PROTEOLYSIS AND CANCER INVASION [J].
ELLIS, V ;
PYKE, C ;
ERIKSEN, J ;
SOLBERG, H ;
DANO, K .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1992, 667 :13-31
[9]  
ELLIS V, 1994, FIBRINOLYSIS DISEASE
[10]  
GRONDAHLHANSEN J, 1988, J LAB CLIN MED, V111, P42